COVID-19 therapy developer Ainos stock falls 17% day after uplisting, $3M IPO

Aug. 10, 2022 1:45 PM ETAinos, Inc. (AIMD)By: Val Kennedy, SA News Editor

Initial Public Offering. IPO. Financial trade. Investment

Andranik Hakobyan/iStock via Getty Images

COVID-19 therapy and test developer Ainos (NASDAQ:AIMD) saw its stock sink 17% Wednesday, the day after it uplisted its shares to Nasdaq and conducted a $3M initial public offering.

Shares of the medtech group

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.